• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

spp. 浆果在预防和治疗非酒精性脂肪肝病中的作用:临床前和临床研究的综合更新。

spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research.

机构信息

Department of Agroenginieering and Quality Analysis, Faculty of Production Engineering, Wroclaw University of Economics and Business, Komandorska 118-120, 53-345 Wrocław, Poland.

Department of Food Technology and Nutrition, Faculty of Production Engineering, Wroclaw University of Economics and Business, Komandorska 118-120, 53-345 Wrocław, Poland.

出版信息

Nutrients. 2024 Sep 2;16(17):2940. doi: 10.3390/nu16172940.

DOI:10.3390/nu16172940
PMID:39275255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11396909/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disorder marked by the buildup of triacylglycerols (TGs) in the liver. It includes a range of conditions, from simple steatosis to more severe forms like non-alcoholic steatohepatitis (NASH), which can advance to fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD's prevalence is rising globally, estimated between 10% and 50%. The disease is linked to comorbidities such as obesity, type 2 diabetes, insulin resistance, and cardiovascular diseases and currently lacks effective treatment options. Therefore, researchers are focusing on evaluating the impact of adjunctive herbal therapies in individuals with NAFLD. One herbal therapy showing positive results in animal models and clinical studies is fruits from the spp. genus. This review presents an overview of the association between consuming fruits, juices, and extracts from spp. and NAFLD. The search used the following keywords: (( OR blueberry OR bilberry OR cranberry) AND ("non-alcoholic fatty liver disease" OR "non-alcoholic steatohepatitis")). Exclusion criteria included reviews, research notes, book chapters, case studies, and grants. The review included 20 studies: 2 clinical trials and 18 studies on animals and cell lines. The findings indicate that juices and extracts from fruits and leaves have significant potential in addressing NAFLD by improving lipid and glucose metabolism and boosting antioxidant and anti-inflammatory responses. In conclusion, blueberries appear to have the potential to alleviate NAFLD, but more clinical trials are needed to confirm these benefits.

摘要

非酒精性脂肪性肝病 (NAFLD) 是一种常见的慢性肝脏疾病,其特征是肝脏中三酰甘油 (TGs) 的积累。它包括一系列病症,从单纯性脂肪变性到更严重的形式,如非酒精性脂肪性肝炎 (NASH),后者可进展为纤维化、肝硬化和肝细胞癌。NAFLD 的全球患病率正在上升,估计在 10%到 50%之间。该疾病与肥胖、2 型糖尿病、胰岛素抵抗和心血管疾病等合并症有关,目前缺乏有效的治疗选择。因此,研究人员专注于评估辅助草药疗法对 NAFLD 患者的影响。一种在动物模型和临床研究中显示出积极结果的草药疗法是 spp. 属的果实。这篇综述介绍了食用 spp. 的果实、果汁和提取物与 NAFLD 之间的关联。搜索使用了以下关键字:((蓝莓 OR 越橘 OR 蔓越莓) AND (非酒精性脂肪性肝病 OR 非酒精性脂肪性肝炎))。排除标准包括评论、研究笔记、书籍章节、案例研究和拨款。综述包括 20 项研究:2 项临床试验和 18 项关于动物和细胞系的研究。研究结果表明, spp. 的果实和叶子的果汁和提取物通过改善脂质和葡萄糖代谢、增强抗氧化和抗炎反应,具有显著的治疗非酒精性脂肪性肝病的潜力。总之,蓝莓似乎有缓解非酒精性脂肪性肝病的潜力,但需要更多的临床试验来证实这些益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d136/11396909/440ce8a3c174/nutrients-16-02940-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d136/11396909/51be0ebbebdd/nutrients-16-02940-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d136/11396909/f81a0da3afc5/nutrients-16-02940-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d136/11396909/440ce8a3c174/nutrients-16-02940-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d136/11396909/51be0ebbebdd/nutrients-16-02940-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d136/11396909/f81a0da3afc5/nutrients-16-02940-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d136/11396909/440ce8a3c174/nutrients-16-02940-g003.jpg

相似文献

1
spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research. spp. 浆果在预防和治疗非酒精性脂肪肝病中的作用:临床前和临床研究的综合更新。
Nutrients. 2024 Sep 2;16(17):2940. doi: 10.3390/nu16172940.
2
Extracts of bilberry ( L.) fruits improve liver steatosis and injury in mice by preventing lipid accumulation and cell death.欧洲越橘(L.)果实提取物通过防止脂质积累和细胞死亡来改善小鼠肝脏脂肪变性和损伤。
Biosci Biotechnol Biochem. 2019 Nov;83(11):2110-2120. doi: 10.1080/09168451.2019.1634514. Epub 2019 Jun 27.
3
Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.植物疗法作为一种多靶点治疗方法应对非酒精性脂肪性肝病的多种病理生理学:实验干预的系统评价。
Medicina (Kaunas). 2021 Aug 14;57(8):822. doi: 10.3390/medicina57080822.
4
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.他汀类药物单独使用,或与吡格列酮及其他药物联合使用,用于治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎及相关心血管风险。专家小组声明。
Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4.
5
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.非酒精性脂肪性肝病治疗在 2 型糖尿病患者中;新的问题出现了。
Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313.
6
Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease.揭示心血管威胁:非酒精性脂肪性肝病中肝纤维化与亚临床动脉粥样硬化的综合研究
Cureus. 2023 Oct 13;15(10):e46946. doi: 10.7759/cureus.46946. eCollection 2023 Oct.
7
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.非酒精性脂肪性肝病全谱的代谢特征
JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477. eCollection 2022 May.
8
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.2型糖尿病合并非酒精性脂肪性肝病患者的治疗:当前方法与未来方向
Diabetologia. 2016 Jun;59(6):1112-20. doi: 10.1007/s00125-016-3952-1. Epub 2016 Apr 21.
9
Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.非酒精性脂肪性肝病:风险因素、病理生理机制、诊断程序和治疗干预的概述。
Life Sci. 2021 Apr 15;271:119220. doi: 10.1016/j.lfs.2021.119220. Epub 2021 Feb 13.
10
Promising therapies for treatment of nonalcoholic steatohepatitis.治疗非酒精性脂肪性肝炎的有前景的疗法。
Expert Opin Emerg Drugs. 2016 Sep;21(3):343-57. doi: 10.1080/14728214.2016.1220533. Epub 2016 Aug 28.

引用本文的文献

1
Identification of biomarkers between coronary artery disease and non-alcoholic steatohepatitis: a combination of bioinformatics and machine learning.冠状动脉疾病与非酒精性脂肪性肝炎之间生物标志物的鉴定:生物信息学与机器学习相结合
Front Genet. 2025 Jul 17;16:1573621. doi: 10.3389/fgene.2025.1573621. eCollection 2025.

本文引用的文献

1
Resmetirom: First Approval.雷美替胺:首次获批
Drugs. 2024 Jun;84(6):729-735. doi: 10.1007/s40265-024-02045-0. Epub 2024 May 21.
2
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.非酒精性脂肪性肝病/代谢功能障碍相关脂肪性肝病的药物治疗进展:聚焦于代谢和肝脏靶向干预措施。
Gastroenterol Rep (Oxf). 2024 Apr 26;12:goae029. doi: 10.1093/gastro/goae029. eCollection 2024.
3
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges.
瑞美替隆,首个获批用于治疗代谢功能障碍相关脂肪性肝炎的药物:试验、机遇与挑战。
Metabolism. 2024 May;154:155835. doi: 10.1016/j.metabol.2024.155835. Epub 2024 Mar 19.
4
Anthocyanins: Potential phytochemical candidates for the amelioration of non-alcoholic fatty liver disease.花色苷:改善非酒精性脂肪性肝病的潜在植物化学候选物。
Ann Pharm Fr. 2024 May;82(3):373-391. doi: 10.1016/j.pharma.2024.02.005. Epub 2024 Feb 13.
5
The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis.SCAP/SREBP 在肝脂肪变性中的脂质代谢中的中心调控作用。
Int J Mol Sci. 2024 Jan 16;25(2):1109. doi: 10.3390/ijms25021109.
6
Advances in embedding techniques of anthocyanins: Improving stability, bioactivity and bioavailability.花青素包埋技术的进展:提高稳定性、生物活性和生物利用度。
Food Chem X. 2023 Nov 7;20:100983. doi: 10.1016/j.fochx.2023.100983. eCollection 2023 Dec 30.
7
Regulation and targeting of SREBP-1 in hepatocellular carcinoma.SREBP-1 在肝细胞癌中的调控和靶向治疗。
Cancer Metastasis Rev. 2024 Jun;43(2):673-708. doi: 10.1007/s10555-023-10156-5. Epub 2023 Dec 1.
8
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery.非酒精性脂肪性肝病:药物传递中的当前治疗方法和未来展望。
J Control Release. 2023 Nov;363:415-434. doi: 10.1016/j.jconrel.2023.09.040. Epub 2023 Oct 1.
9
Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention.非酒精性脂肪性肝病的药物治疗:基于代谢干预的新机遇
Nutr Metab (Lond). 2023 Jul 6;20(1):30. doi: 10.1186/s12986-023-00748-x.
10
Five blueberry anthocyanins and their antioxidant, hypoglycemic, and hypolipidemic effects .五种蓝莓花青素及其抗氧化、降血糖和降血脂作用。
Front Nutr. 2023 May 18;10:1172982. doi: 10.3389/fnut.2023.1172982. eCollection 2023.